Topics

Integrin Beta 7 Gut Homing Receptor Beta Subunit or ITGB7 Pipeline Review, H1 2019 [Published by Global Markets Direct] Prices from USD $3500

21:02 EDT 13 Aug 2019 | BioPortfolio Reports

Integrin Beta 7 Gut Homing Receptor Beta Subunit or ITGB7 Pipeline Review, H1 2019


Summary


According to the recently published report 'Integrin Beta 7 Pipeline Review, H1 2019'; Integrin Beta 7 Gut Homing Receptor Beta Subunit or ITGB7 pipeline Target constitutes close to 7 molecules.


Integrin Beta 7 Gut Homing Receptor Beta Subunit or ITGB7 Integrin beta7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interactions involve the tripeptide LDT in MADCAM1, and LDV in fibronectin. It binds to HIV1 gp120 that allows the virus to enter GALT major trigger of AIDS disease.


The report 'Integrin Beta 7 Pipeline Review, H1 2019' outlays comprehensive information on the Integrin Beta 7 Gut Homing Receptor Beta Subunit or ITGB7 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.


It also reviews key players involved in Integrin Beta 7 Gut Homing Receptor Beta Subunit or ITGB7 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in PreRegistration, Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1 and 3 respectively. Report covers products from therapy areas Gastrointestinal, Immunology, Infectious Disease and Undisclosed which include indications Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease Regional Enteritis, Graft Versus Host Disease GVHD, Human Immunodeficiency Virus HIV Infections AIDS and Unspecified.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 Gut Homing Receptor Beta Subunit or ITGB7

The report reviews Integrin Beta 7 Gut Homing Receptor Beta Subunit or ITGB7 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Integrin Beta 7 Gut Homing Receptor Beta Subunit or ITGB7 targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Beta 7 Gut Homing Receptor Beta Subunit or ITGB7 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Beta 7 Gut Homing Receptor Beta Subunit or ITGB7 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Integrin Beta 7 Gut Homing Receptor Beta Subunit or ITGB7

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrin Beta 7 Gut Homing Receptor Beta Subunit or ITGB7 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Integrin Beta 7 Gut Homing Receptor Beta Subunit or ITGB7 Pipeline Review, H1 2019 [Published by Global Markets Direct] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Integrin Beta 7 Gut Homing Receptor Beta Subunit or ITGB7 Pipeline Review, H1 2019 [Published by Global Markets Direct] Prices from USD $3500"

Quick Search

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...